What is the projected market valuation of the Autoimmune Disease Treatment Market by 2035?

The projected market valuation for the market is expected to reach 38.42 USD Billion by 2035. Read More

What was the market valuation of the market in 2024?

The overall market valuation was 18.23 USD Billion in 2024. Read More

What is the expected CAGR for the Autoimmune Disease Treatment Market during the forecast period 2025 - 2035?

The expected CAGR for the market during the forecast period 2025 - 2035 is 7.01%. Read More

Which therapy type segment is projected to have the highest valuation by 2035?

The Biologics segment is projected to reach a valuation of 12.5 USD Billion by 2035. Read More

How does the market for Rheumatoid Arthritis treatments compare to that for Multiple Sclerosis?

The market for Rheumatoid Arthritis treatments is projected to reach 10.5 USD Billion, while Multiple Sclerosis is expected to reach 8.5 USD Billion by 2035. Read More

What is the anticipated growth in the Injectable route of administration segment by 2035?

The Injectable route of administration segment is expected to grow to 16.0 USD Billion by 2035. Read More

Which end-user segment is projected to dominate the market by 2035?

The Hospitals end-user segment is projected to dominate the market, reaching 15.0 USD Billion by 2035. Read More

What role do key players like AbbVie and Roche play in the Autoimmune Disease Treatment Market?

Key players such as AbbVie and Roche are likely to lead the market, contributing to innovations and competitive strategies. Read More

What is the projected valuation for the Corticosteroids segment by 2035?

The Corticosteroids segment is projected to reach a valuation of 9.0 USD Billion by 2035. Read More

How does the market for Homecare Settings compare to that for Clinics by 2035?

The Homecare Settings market is expected to reach 13.42 USD Billion, compared to 10.0 USD Billion for Clinics by 2035. Read More

Autoimmune Disease Treatment Market

Autoimmune Disease Treatment Market Research Report: Size, Share, Trend Analysis By Therapy Type (Biologics, Corticosteroids, Immunosuppressants, Small Molecule Drugs), By Disease Type (Rheumatoid Arthritis, Multiple Sclerosis, Lupus, Psoriasis, Inflammatory Bowel Disease), By Route of Administration (Oral, Injectable, Topical), By End-user (Hospitals, Clinics, Homecare Settings), and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

7.01%

2024 Market Size

$ 18.23 Billion

2035 Market Size

$ 38.42 Billion

Pharmaceutical ● Updated August 2026 Report ID: MRFR/Pharma/4137-HCR | Pages: 200 | Author: Vikita Thakur, Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Therapy Type (USD Billion) | |
  1. 4.1.1 Biologics | |
  2. 4.1.2 Corticosteroids | |
  3. 4.1.3 Immunosuppressants | |
  4. 4.1.4 Small Molecule Drugs |
2. 4.2 Healthcare, BY Disease Type (USD Billion) | |
  1. 4.2.1 Rheumatoid Arthritis | |
  2. 4.2.2 Multiple Sclerosis | |
  3. 4.2.3 Lupus | |
  4. 4.2.4 Psoriasis | |
  5. 4.2.5 Inflammatory Bowel Disease |
3. 4.3 Healthcare, BY Route of Administration (USD Billion) | |
  1. 4.3.1 Oral | |
  2. 4.3.2 Injectable | |
  3. 4.3.3 Topical |
4. 4.4 Healthcare, BY End-user (USD Billion) | |
  1. 4.4.1 Hospitals | |
  2. 4.4.2 Clinics | |
  3. 4.4.3 Homecare Settings |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 AbbVie (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Roche (CH) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Johnson & Johnson (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Amgen (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Bristol-Myers Squibb (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Gilead Sciences (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Sanofi (FR) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Merck & Co. (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Novartis (CH) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY THERAPY TYPE |
7. 6.4 US MARKET ANALYSIS BY DISEASE TYPE |
8. 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
9. 6.6 US MARKET ANALYSIS BY END-USER |
10. 6.7 CANADA MARKET ANALYSIS BY THERAPY TYPE |
11. 6.8 CANADA MARKET ANALYSIS BY DISEASE TYPE |
12. 6.9 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
13. 6.10 CANADA MARKET ANALYSIS BY END-USER |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY THERAPY TYPE |
16. 6.13 GERMANY MARKET ANALYSIS BY DISEASE TYPE |
17. 6.14 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
18. 6.15 GERMANY MARKET ANALYSIS BY END-USER |
19. 6.16 UK MARKET ANALYSIS BY THERAPY TYPE |
20. 6.17 UK MARKET ANALYSIS BY DISEASE TYPE |
21. 6.18 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
22. 6.19 UK MARKET ANALYSIS BY END-USER |
23. 6.20 FRANCE MARKET ANALYSIS BY THERAPY TYPE |
24. 6.21 FRANCE MARKET ANALYSIS BY DISEASE TYPE |
25. 6.22 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
26. 6.23 FRANCE MARKET ANALYSIS BY END-USER |
27. 6.24 RUSSIA MARKET ANALYSIS BY THERAPY TYPE |
28. 6.25 RUSSIA MARKET ANALYSIS BY DISEASE TYPE |
29. 6.26 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
30. 6.27 RUSSIA MARKET ANALYSIS BY END-USER |
31. 6.28 ITALY MARKET ANALYSIS BY THERAPY TYPE |
32. 6.29 ITALY MARKET ANALYSIS BY DISEASE TYPE |
33. 6.30 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
34. 6.31 ITALY MARKET ANALYSIS BY END-USER |
35. 6.32 SPAIN MARKET ANALYSIS BY THERAPY TYPE |
36. 6.33 SPAIN MARKET ANALYSIS BY DISEASE TYPE |
37. 6.34 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
38. 6.35 SPAIN MARKET ANALYSIS BY END-USER |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY THERAPY TYPE |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY DISEASE TYPE |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY END-USER |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY THERAPY TYPE |
45. 6.42 CHINA MARKET ANALYSIS BY DISEASE TYPE |
46. 6.43 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
47. 6.44 CHINA MARKET ANALYSIS BY END-USER |
48. 6.45 INDIA MARKET ANALYSIS BY THERAPY TYPE |
49. 6.46 INDIA MARKET ANALYSIS BY DISEASE TYPE |
50. 6.47 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
51. 6.48 INDIA MARKET ANALYSIS BY END-USER |
52. 6.49 JAPAN MARKET ANALYSIS BY THERAPY TYPE |
53. 6.50 JAPAN MARKET ANALYSIS BY DISEASE TYPE |
54. 6.51 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
55. 6.52 JAPAN MARKET ANALYSIS BY END-USER |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY THERAPY TYPE |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY DISEASE TYPE |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY END-USER |
60. 6.57 MALAYSIA MARKET ANALYSIS BY THERAPY TYPE |
61. 6.58 MALAYSIA MARKET ANALYSIS BY DISEASE TYPE |
62. 6.59 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
63. 6.60 MALAYSIA MARKET ANALYSIS BY END-USER |
64. 6.61 THAILAND MARKET ANALYSIS BY THERAPY TYPE |
65. 6.62 THAILAND MARKET ANALYSIS BY DISEASE TYPE |
66. 6.63 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
67. 6.64 THAILAND MARKET ANALYSIS BY END-USER |
68. 6.65 INDONESIA MARKET ANALYSIS BY THERAPY TYPE |
69. 6.66 INDONESIA MARKET ANALYSIS BY DISEASE TYPE |
70. 6.67 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
71. 6.68 INDONESIA MARKET ANALYSIS BY END-USER |
72. 6.69 REST OF APAC MARKET ANALYSIS BY THERAPY TYPE |
73. 6.70 REST OF APAC MARKET ANALYSIS BY DISEASE TYPE |
74. 6.71 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
75. 6.72 REST OF APAC MARKET ANALYSIS BY END-USER |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY THERAPY TYPE |
78. 6.75 BRAZIL MARKET ANALYSIS BY DISEASE TYPE |
79. 6.76 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
80. 6.77 BRAZIL MARKET ANALYSIS BY END-USER |
81. 6.78 MEXICO MARKET ANALYSIS BY THERAPY TYPE |
82. 6.79 MEXICO MARKET ANALYSIS BY DISEASE TYPE |
83. 6.80 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
84. 6.81 MEXICO MARKET ANALYSIS BY END-USER |
85. 6.82 ARGENTINA MARKET ANALYSIS BY THERAPY TYPE |
86. 6.83 ARGENTINA MARKET ANALYSIS BY DISEASE TYPE |
87. 6.84 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
88. 6.85 ARGENTINA MARKET ANALYSIS BY END-USER |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPY TYPE |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE TYPE |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USER |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY THERAPY TYPE |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY DISEASE TYPE |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END-USER |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY THERAPY TYPE |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY DISEASE TYPE |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END-USER |
102. 6.99 REST OF MEA MARKET ANALYSIS BY THERAPY TYPE |
103. 6.100 REST OF MEA MARKET ANALYSIS BY DISEASE TYPE |
104. 6.101 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
105. 6.102 REST OF MEA MARKET ANALYSIS BY END-USER |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY THERAPY TYPE, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY THERAPY TYPE, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY DISEASE TYPE, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY DISEASE TYPE, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY END-USER, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY END-USER, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY END-USER, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY END-USER, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY END-USER, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY END-USER, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY END-USER, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY END-USER, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY END-USER, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY END-USER, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY END-USER, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY END-USER, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY END-USER, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY END-USER, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY END-USER, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY END-USER, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY END-USER, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY END-USER, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY END-USER, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY END-USER, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY END-USER, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY END-USER, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY END-USER, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY END-USER, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY END-USER, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY END-USER, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY END-USER, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY END-USER, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY END-USER, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY END-USER, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY THERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY END-USER, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Autoimmune Disease Treatment Market Segmentation

Autoimmune Disease Treatment Market By Therapy Type (USD Billion, 2025-2035)

Biologics
Corticosteroids
Immunosuppressants
Small Molecule Drugs

Autoimmune Disease Treatment Market By Disease Type (USD Billion, 2025-2035)

Rheumatoid Arthritis
Multiple Sclerosis
Lupus
Psoriasis
Inflammatory Bowel Disease

Autoimmune Disease Treatment Market By Route of Administration (USD Billion, 2025-2035)

Oral
Injectable
Topical

Autoimmune Disease Treatment Market By End-user (USD Billion, 2025-2035)

Hospitals
Clinics
Homecare Settings

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”